Convergence of gene and cell therapy

Regenerative Medicine

Volumn 7, Issue 6 SUPPL., 2012, Pages 50-56

  Bersenev, Alexey ^a   Levine, Bruce L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cell therapy; Clinical trial; Gene therapy; Immunotherapy

Indexed keywords

ANTIVIRAL RESISTANCE; ARTICLE; CELL BASED GENE THERAPY; CELL ENGINEERING; CELL FATE; CELL FUNCTION; CELL TRACKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DNA MODIFICATION; GENE TRANSFER; GENETIC DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOCOMPETENT CELL; PATIENT SAFETY; PRIORITY JOURNAL;

DRUG RESISTANCE, VIRAL; GENETIC DISEASES, INBORN; GENETIC THERAPY; HUMANS; LYMPHOCYTES; TISSUE THERAPY; TROPISM;

EID: 84870685162     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.12.71     Document Type: Article

References (43)

1. Muul LM, Tuschong LM, Soenen SL et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101(7), 2563-2569 (2003).
2. Riviere I, Dunbar CE, Sadelain M. Hematopoietic stem cell engineering at a crossroads. Blood 119(5), 1107-1116 (2012).
3. Aiuti A, Roncarolo MG. Ten years of gene therapy for primary immune deficiencies. Hematology Am. Soc. Hematol. Educ. Program 682-689 (2009).
4. Aiuti A, Cattaneo F, Galimberti S et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360(5), 447-458 (2009).
5. Gaspar HB, Cooray S, Gilmour KC et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to longterm immunological recovery and metabolic correction. Sci. Transl. Med. 3(97), 97ra80 (2011).
6. Hacein-Bey-Abina S, Hauer J, Lim A et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363(4), 355-364 (2010).
7. Boztug K, Schmidt M, Schwarzer A et al. Stem-cell gene therapy for the Wiskott- Aldrich syndrome. N. Engl. J. Med. 363(20), 1918-1927 (2010).
8. Kang EM, Choi U, Theobald N. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 115(4), 783-791 (2010).
9. Ott MG, Schmidt M, Schwarzwaelder K et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12(4), 401-409 (2006).
10. Hacein-Bey-Abina S, von Kalle C, Schmidt M et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302(5644), 415-419 (2003).
11. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat. Rev. Genet. 12(5), 316-328 (2011).
12. Scaramuzza S, Biasco L, Ripamonti A et al. Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol. Ther. doi: 10.1038/mt.2012.2310 (2012) (Epub ahead of print).
13. Booth C, Gaspar HB, Thrasher AJ. Gene therapy for primary immunodeficiency. Curr. Opin. Pediatr. 23(6), 659-666 (2011).
14. Montini E, Cesana D, Schmidt M et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24(6), 687-696 (2006).
15. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86(24), 10024-10028 (1989).
16. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21(2), 215-223 (2009).
17. Kohn DB, Dotti G, Brentjens R et al. CARs on track in the clinic. Mol. Ther. 19(3), 432-438 (2011).
18. Pinthus JH, Waks T, Kaufman-Francis K et al. Immuno-gene therapy of established prostate tumors using chimeric receptorredirected human lymphocytes. Cancer Res. 63(10), 2470-2476 (2003).
19. Kershaw MH, Westwood JA, Parker LL et al. 2006. A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12(20 Pt 1), 6106-6115.
20. Lamers CH, Sleijfer S, Vulto AG et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24(13), e20-e22 (2006).
21. Lamers CH, Willemsen R, van Elzakker P et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117(1), 72-82 (2011).
22. Pule MA, Savoldo B, Myers GD et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14(11), 1264-1270 (2008).
23. Louis CU, Savoldo B, Dotti G et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118(23), 6050-6056 (2011).
24. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3(95), 95ra73 (2011).
25. Porter DL, Levine BL, Kalos M, Bagg A, CH June. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011).
26. Scholler N, Fu N, Yang Y et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl Acad. Sci. USA 96(20), 11531-11536 (1999).
27. Brentjens R, Yeh T, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a Phase I clinical trial. Mol. Ther. 18(4), 666-668 (2010).
28. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18(4), 843-851 (2010).
29. Siliciano JD, Kajdas J, Finzi D et al. Longterm follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4(+) T cells. Nat. Med. 9(6), 727-728 (2003).
30. Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat. Biotechnol. 25(12), 1444-1454 (2007).
31. Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiplyexposed individuals to HIV-1 infection. Cell 86(3), 367-377 (1996).
32. Hutter G, Nowak D, Mossner M et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360(7), 692-698 (2009).
33. Allers K, Hutter G, Hofmann J et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 117(10), 2791-2799 (2011).
34. Urnov FD, Miller JC, Lee YL et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435(7042), 646-651 (2005).
35. Perez EE, Wang J, Miller JC et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26(7), 808-816 (2008).
36. Tiberghien P, Ferrand C, Lioure B et al. Administration of herpes simplexthymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97(1), 63-72 (2001).
37. Ciceri F, Bonini C, Stanghellini MT et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a nonrandomised Phase I-II study. Lancet Oncol. 10(5), 489-500 (2009).
38. Di Stasi A, Tey SK, Dotti G et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365(18), 1673-1683 (2011).
39. Zhao Y, Moon E, Carpenito C et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70(22), 9053-9061 (2010).
40. Yin J, Kim JK, Moon JH et al. hMSCmediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence. Mol. Ther. 19(6), 1161-1169 (2011).
41. Joo KM, Park IH, Shin JY et al. Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol. Ther. 17(3), 570-575 (2009).
42. Kim SU, Jeung EB, Kim YB, Cho MH, Choi KC. Potential tumor-tropic effect of genetically engineered stem cells expressing suicide enzymes to selectively target invasive cancer in animal models. Anticancer Res. 31(4), 1249-1258 (2011).
43. Sarkar D, Spencer JA, Phillips JA et al. Engineered cell homing. Blood 118(25) e184-e191 (2011).